Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On August 14, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for the second quarter of 2024 and provided a business update.</li><li>The company recently completed enrollment in the single ascending dose (SAD) Part 1 portion of the Phase 1 trial of DA-1726 and we anticipate topline results in the third quarter of 2024.</li><li>The multiple ascending dose (MAD) Part 2 portion of the Phase 1 trial is enrolling and topline results are expected in the first quarter of 2025.</li></ul>

On August 14, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for the second quarter of 2024 and provided a business update.The company recently completed enrollment in the single ascending dose (SAD) Part 1 portion of the Phase 1 trial of DA-1726 and we anticipate topline results in the third quarter of 2024.The multiple ascending dose (MAD) Part 2 portion of the Phase 1 trial is enrolling and topline results are expected in the first quarter of 2025.

NRBO:  Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24 

<ul><li>On May 22, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced that preclinical data of DA-1241 in combination with semaglutide in mouse models of metabolic dysfunction-associated steatohepatitis (MASH) will be presented at the EASL Congress 2024 on Thursday, June 6, 2024.</li><li>Two abstracts will be presented: one using the GAN diet-induced obese and biopsy-confirmed mouse model of MASH and one using the CCl4 induced liver fibrosis model.</li><li>The company shared some of the results that showed an additive effect on different parameters of liver health in both models, with the posters being available following the presentations.</li></ul>

On May 22, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced that preclinical data of DA-1241 in combination with semaglutide in mouse models of metabolic dysfunction-associated steatohepatitis (MASH) will be presented at the EASL Congress 2024 on Thursday, June 6, 2024.Two abstracts will be presented: one using the GAN diet-induced obese and biopsy-confirmed mouse model of MASH and one using the CCl4 induced liver fibrosis model.The company shared some of the results that showed an additive effect on different parameters of liver health in both models, with the posters being available following the presentations.

NRBO:  Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024 

United States

MetaVia Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing dual oxyntomodulin (OXM) analog agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). MetaVia serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MetaVia (MTVA US)

NRBO: Data from Part 1 of Phase 1 Trial of DA-1726 in 3Q24

On August 14, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for the second quarter of 2024 and provided a business...

Zacks Small Cap Research

NRBO: Preclinical Data on DA-1241 with Semaglutide to be Presented at EASL Congress 2024

On May 22, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced that preclinical data of DA-1241 in combination with semaglutide in mouse models...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)